Selection of Suitable Prodrug Candidates for in vivo Studies via in vitro Studies; The correlation of Prodrug Stability in Between Cell Culture Homogenates and Human Tissue Homogenates

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 3, 2012, Pages 433-446

  Tsume, Yasuhiro ^a   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' O DEXTRO VALYLFLUOXURIDINE; 5' O PHENYLALANYLTYROSYLFLUOXURIDINE; FLOXURIDINE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL CULTURE HOMOGENATE; CELL STRAIN ASPC 1; CELL STRAIN CACO 2; CELL STRAIN CAPAN 2; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; HOMOGENATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER MICROSOME; PANCREAS; PANCREAS CELL; PREDICTION; SMALL INTESTINE; TISSUE HOMOGENATE;

EID: 84865075565     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j36k6z     Document Type: Article

References (58)

1. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev. 2001;46(1-3):27-43.
2. Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA. Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods. 2000;44(1):313-24.
3. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 1989;96(3):736-49.
4. Li AP. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today. 2001;6(7):357-66.
5. Matsumoto S, Saito H, Inui K. Transcellular transport of oral cephalosporins in human intestinal epithelial cells, Caco-2: interaction with dipeptide transport systems in apical and basolateral membranes. J Pharmacol Exp Ther. 1994;270(2):498-504.
6. Phung-Ba V, Warnery A, Scherman D, Wils P. Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells. Eur J Pharmacol. 1995;288(2):187-92.
7. Gupta D, Gupta SV, Lee KD, Amidon GL. Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol Pharm. 2009;6(5):1604-11.
8. Katragadda S, Jain R, Kwatra D, Hariharan S, Mitra AK. Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells. Int J Pharm. 2008;362(1-2):93-101.
9. Najlah M, Freeman S, Attwood D, D'Emanuele A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int J Pharm. 2007;336(1):183-90.
10. Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, Teramura T. A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos. 2010;38(2):308-16.
11. Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V. In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001;29(10):1269-76.
12. Chiba M, Hensleigh M, Lin JH. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem Pharmacol. 1997;53(8):1187-95.
13. Tsume Y, Hilfinger JM, Amidon GL. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm. 2008;5(5):717-27.
14. Tsume Y, Vig BS, Sun J, Landowski CP, Hilfinger JM, Ramachandran C, et al. Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules. 2008;13(7):1441-54.
15. Blanchard N, Hewitt NJ, Silber P, Jones H, Coassolo P, Lave T. Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations. J Pharm Pharmacol. 2006;58(5):633-41.
16. Chiba M, Ishii Y, Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development. Aaps J. 2009;11(2):262-76.
17. Shibata Y, Takahashi H, Chiba M, Ishii Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos. 2002;30(8):892-6.
18. Ubeaud G, Schmitt C, Jaeck D, Lave T, Coassolo P. Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica. 1995;25(12):1381-90.
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.
20. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995;82(1):111-5.
21. Bramhall SR, Neoptolemos JP. Advances in diagnosis and treatment of pancreatic cancer. Gastroenterologist. 1995;3(4):301-10.
22. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-30.
23. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18(4):299-313.
24. Grem JL, Harold N, Shapiro J, Bi DQ, Quinn MG, Zentko S, et al. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors. J Clin Oncol. 2000;18(23):3952-63.
25. Laskin JD, Evans RM, Slocum HK, Burke D, Hakala MT. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res. 1979;39(2 Pt 1):383-90.
26. Yamada M, Nakagawa H, Fukushima M, Shimizu K, Hayakawa T, Ikenaka K. In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors. J Neurooncol. 1998;37(2):115-21.
27. Landowski CP, Vig BS, Song X, Amidon GL. Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther. 2005;4(4):659-67.
28. Tsume Y, Hilfinger JM, Amidon GL. Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors:a two-tier monolayer in vitro study. Pharm Res. 2011;28(10):2575-88. doi:10.1007/s11095-011-0485-7.
29. Mittal S, Song X, Vig BS, Amidon GL. Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma. Pharm Res. 2007;24(7):1290-8.
30. Song X, Lorenzi PL, Landowski CP, Vig BS, Hilfinger JM, Amidon GL. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm. 2005;2(2):157-67.
31. Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, et al. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res. 2003;20(9):1381-8.
32. Tsume Y, Provoda CJ, Amidon GL. The achievement of mass balance by simultaneous quantification of loxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, alpha-fluoro-beta-ureidopropionate, lpha-fluoro-beta-alanine using LC-MS. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2011;879(13-14):915-20. doi:10.1016/j.jchromb.2011.02.045.
33. Foger F, Kopf A, Loretz B, Albrecht K, Bernkop-Schnurch A. Correlation of in vitro and in vivo models for the oral absorption of peptide drugs. Amino Acids. 2008;35(1):233-41.
34. Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci. 1996;85(10):1070-6.
35. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man--fact or myth. Pharm Res. 1997;14(6):763-6.
36. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol. 1999;39(8):800-4.
37. Purifoy DJ, Beauchamp LM, de Miranda P, Ertl P, Lacey S, Roberts G, et al. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol. 1993;Suppl 1:139-45.
38. Kim I, Chu XY, Kim S, Provoda CJ, Lee KD, Amidon GL. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem. 2003;278(28):25348-56. doi: 10.1074/jbc.M302055200M302055200 [pii]
39. Kim I, Song X, Vig BS, Mittal S, Shin HC, Lorenzi PJ, et al. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm. 2004;1(2):117-27.
40. Lai L, Xu Z, Zhou J, Lee KD, Amidon GL. Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem. 2008;283(14):9318-27. doi: M709530200[pii] 10.1074/jbc.M709530200.
41. Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998;246(2):470-5.
42. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, et al. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998;15(8):1154-9.
43. Anand BS, Katragadda S, Mitra AK. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. J Pharmacol Exp Ther. 2004;311(2):659-67. doi:10.1124/jpet.104.069997jpet.104.069997 [pii]
44. Eriksson AH, Elm PL, Begtrup M, Nielsen R, Steffansen B, Brodin B. hPEPT1 affinity and translocation of selected Gln-Sar and Glu-Sar dipeptide derivatives. Mol Pharm. 2005;2(3):242-9. doi: 10.1021/mp050015+.
45. Friedrichsen GM, Chen W, Begtrup M, Lee CP, Smith PL, Borchardt RT. Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells. Eur J Pharm Sci. 2002;16(1-2):1-13. doi: S0928098702000477 [pii].
46. Li J, Tamura K, Lee CP, Smith PL, Borchardt RT, Hidalgo IJ. Structure-affinity relationships of Val-Val and Val-Val-Val stereoisomers with the apical oligopeptide transporter in human intestinal Caco-2 cells. J Drug Target. 1998;5(5):317-27. doi:10.3109/10611869808997860.
47. Tamura K, Bhatnagar PK, Takata JS, Lee CP, Smith PL, Borchardt RT. Metabolism, uptake, and transepithelial transport of the diastereomers of Val-Val in the human intestinal cell line, Caco-2. Pharm Res. 1996;13(8):1213-8.
48. Landowski CP, Lorenzi PL, Song X, Amidon GL. Nucleoside ester prodrug substrate specificity of liver carboxylesterase. J Pharmacol Exp Ther. 2006;316(2):572-80.
49. Lorenzi PL, Landowski CP, Song X, Borysko KZ, Breitenbach JM, Kim JS, et al. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J Pharmacol Exp Ther. 2005;314(2):883-90.
50. Friedrichsen GM, Jakobsen P, Taub M, Begtrup M. Application of enzymatically stable dipeptides for enhancement of intestinal permeability. Synthesis and in vitro evaluation of dipeptide-coupled compounds. Bioorg Med Chem. 2001;9(10):2625-32.
51. Friedrichsen GM, Nielsen CU, Steffansen B, Begtrup M. Model prodrugs designed for the intestinal peptide transporter. A synthetic approach for coupling of hydroxy-containing compounds to dipeptides. Eur J Pharm Sci. 2001;14(1):13-9.
52. Dubowchik GM, Walker MA. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther. 1999;83(2):67-123.
53. Gullbo J, Wickstrom M, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, et al. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target. 2003;11(6):355-63.
54. Xing R, Wu F, Mason RW. Control of breast tumor cell growth using a targeted cysteine protease inhibitor. Cancer Res. 1998;58(5):904-9.
55. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31(7):815-32. doi: 10.1124/dmd.31.7.815 31/7/815[pii].
56. Jia L, Liu X. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab. 2007;8(8):822-9.
57. Masri FA, Comhair SA, Koeck T, Xu W, Janocha A, Ghosh S, et al. Abnormalities in nitric oxide and its erivatives in lung cancer. Am J Respir Crit Care Med. 2005;172(5):597-605. doi: 200411-1523OC [pii] 10.1164/rccm.200411-1523OC.
58. Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ, et al. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis. 1998;19(2):291-8+446.